Tanihara M, Suzuki Y, Fujiwara C, Abe C, Abe E, Suda T, Mizushima Y
Kuraray Central Research Laboratory, Okayama, Japan.
Biochem Biophys Res Commun. 1992 Oct 30;188(2):912-20. doi: 10.1016/0006-291x(92)91142-d.
A synthetic peptide corresponding to 86-93 of the human type I IL-1 receptor and its analogues bound human recombinant (hr) IL-1 (alpha and beta) and inhibited dose-dependently both Con A-stimulated proliferation of mouse spleen cells and hrIL-1 beta-stimulated formation of tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells in rat bone marrow cell cultures. Furthermore, hrIL-1 beta-induced mouse paw edema was dose-dependently inhibited by systemic administration (ip) of the synthetic peptide. These results suggest that one of the IL-1 binding sites of the human type I IL-1 receptor comes to the region of 86-93 and the synthetic peptide having the ability to bind hrIL-1 (alpha and beta) blocks the biological activities of exogenous hrIL-1 beta and endogenous mouse IL-1.
一种对应于人I型白细胞介素-1受体86 - 93位的合成肽及其类似物可与人重组白细胞介素-1（α和β）结合，并剂量依赖性地抑制刀豆球蛋白A刺激的小鼠脾细胞增殖以及人重组白细胞介素-1β刺激的大鼠骨髓细胞培养物中抗酒石酸酸性磷酸酶（TRAP）阳性多核细胞的形成。此外，通过腹腔注射全身性给予该合成肽可剂量依赖性地抑制人重组白细胞介素-1β诱导的小鼠爪肿胀。这些结果表明，人I型白细胞介素-1受体的白细胞介素-1结合位点之一位于86 - 93位区域，并且具有结合人重组白细胞介素-1（α和β）能力的合成肽可阻断外源性人重组白细胞介素-1β和内源性小鼠白细胞介素-1的生物学活性。
